Haohai Biological Technology Bundle
What is the history of Haohai Biological Technology?
Established in Shanghai on January 24, 2007, Haohai Biological Technology has become a key player in China's biotech industry. The company achieved a significant milestone by becoming the first biopharmaceutical firm to be listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market.
The company's initial focus was on utilizing biomedical material technology and genetic engineering to develop and market medical devices and pharmaceuticals, aiming to replace imported products.
What is Brief History of Haohai Biological Technology Company?
Founded in 2007, Haohai Biological Technology has established itself as a leader in China's biotechnology landscape. Its dual listing on the Hong Kong Stock Exchange in 2015 and the Shanghai Stock Exchange STAR Market in 2019 marked a significant achievement. The company has consistently held the top market share in ophthalmic viscoelastic agents and surgical anti-adhesion agents for 17 years, and in orthopedic joint cavity viscoelastic supplements for 10 years. In 2024, its revenue reached CNY 2,697.66 million. The company's product portfolio includes offerings like Haohai Biological Technology PESTEL Analysis, showcasing its diverse range of solutions.
What is the Haohai Biological Technology Founding Story?
The founding story of Haohai Biological Technology is rooted in a vision to address the market's need for advanced absorbable biomedical materials and innovative medical solutions within China. Established on January 24, 2007, in Shanghai, the company's inception was driven by the foresight of its ultimate controlling shareholders, Mr. Jiang Wei and Ms. You Jie.
The Genesis of Haohai Biological Technology
Haohai Biological Technology's journey began with a clear objective: to achieve import substitution in China's biomedical sector. The founders identified a significant market gap for high-quality medical devices and pharmaceuticals derived from cutting-edge biomedical material technology and genetic engineering.
- Official establishment: January 24, 2007, in Shanghai, PRC.
- Founders' vision: Import substitution in biomedical materials and medical solutions.
- Initial focus: Biologicals, medical hyaluronate, and ophthalmology products.
- Strategic acquisitions: Three HA manufacturers in 2007 to build product portfolio and production capabilities.
The company's initial business model was strategically designed to manufacture and sell biologicals, medical hyaluronate, and ophthalmology products. A pivotal moment in the Haohai Biological Technology company's early development was the acquisition of three hyaluronic acid (HA) manufacturers in 2007: Songjiang Factory, Shanghai Jianhua, and Qisheng Biological. These acquisitions were instrumental in rapidly establishing the company's presence in key therapeutic areas such as ophthalmology, orthopedics, and general surgery. This strategic move allowed Haohai Biological Technology to quickly expand its product offerings and enhance its manufacturing capacity, laying a robust foundation for its future growth and market leadership. The Brief History of Haohai Biological Technology details these foundational steps.
Haohai Biological Technology SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Haohai Biological Technology?
The Haohai Biological Technology company's journey began in 2007, marked by a strategic focus on absorbable biomedical materials. Its early years were defined by aggressive expansion and key acquisitions that quickly established its market presence.
Founding and Initial Acquisitions
Established in 2007, Haohai Biological Technology's founding involved the immediate acquisition of three hyaluronic acid manufacturers: Songjiang Factory, Shanghai Jianhua, and Qisheng Biological. This move significantly broadened its reach within the ophthalmology, orthopedics, and general surgery sectors, laying the groundwork for its specialization in absorbable biomedical materials.
Entry into Medical Aesthetics and Market Validation
A pivotal moment in the company's early development was the 2012 launch of its first-generation dermal filler, 'Martrifill,' signifying its entry into the lucrative medical aesthetics market. Further validation came with its H shares listing on The Stock Exchange of Hong Kong Limited's Main Board on April 30, 2015, a significant capital raise that underscored investor confidence.
Expansion in Ophthalmology and Dual Listing
In 2015, the company bolstered its ophthalmology division through a merger with six intraocular lens (IOL) related entities, creating a complete IOL industry chain. This strategic move solidified its position in the Chinese artificial IOL market. The company's growth trajectory continued with its A shares listing on the Shanghai Stock Exchange's Sci-tech Innovation Board on October 30, 2019, making it the first biopharmaceutical firm in China to be listed on both Hong Kong and the SSE STAR Market.
Sustained Market Leadership
Throughout its expansion, Haohai Biological Technology consistently maintained market leadership. As of 2023, it had held the top position in ophthalmic viscoelastic agents and surgical anti-adhesion agents for 17 consecutive years, and in orthopedic joint cavity viscoelastic supplements for 10 consecutive years. This sustained market dominance reflects its strategic acquisitions, product innovation, and effective capital market strategies, positioning it as a key player in the biomedical industry and a company to watch within the Competitors Landscape of Haohai Biological Technology.
Haohai Biological Technology PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Haohai Biological Technology history?
The Haohai Biological Technology company history is marked by significant achievements and strategic advancements, alongside navigating market complexities. From its inception, the company has focused on innovation and expansion within the biotechnology sector, particularly in ophthalmology and medical aesthetics. This journey reflects a commitment to developing advanced medical products and broadening its market presence through strategic acquisitions and research initiatives.
| Year | Milestone |
|---|---|
| 2019 | Achieved industry first with approval of domestic hydrophilic aspheric IOL and launched 'Optimum Infinite.' |
| 2020 | Acquired Hangzhou Aijinglun for refractive lens PRL and received approval for third-generation dermal filler, Hyalumatrix. |
| 2021 | Expanded into photoelectric equipment via JUVA acquisition, invested in Eirion (botulinum toxin), and secured OK lens distribution rights. Acquired Hebei Xinshikang for soft contact lens market entry. |
| July 2024 | Received approval for 'Hyalumatrix MoomWhite,' the world's first independently developed organic cross-linked HA Dermal Filler. |
| May 2025 | Had 23 projects under research, with 9 in medical aesthetics and 9 in ophthalmology. |
| End of 2023 | Applied for over 500 patents, with more than 100 granted invention patents and dozens of international invention patents. |
Haohai Biological Technology has consistently pushed the boundaries of innovation, notably with the development of the world's first organic cross-linked HA Dermal Filler, 'Hyalumatrix MoomWhite,' approved in July 2024. The company's robust R&D pipeline, with 23 projects underway as of May 2025, including 9 in medical aesthetics and 9 in ophthalmology, highlights its dedication to advancing medical technologies and expanding its product portfolio.
Ophthalmic Innovations
In 2019, the company achieved a significant milestone with the approval of the domestic hydrophilic aspheric IOL, marking a key advancement in ophthalmic lens technology.
Dermal Filler Advancement
The launch of its third-generation dermal filler, Hyalumatrix, in 2020, followed by the groundbreaking 'Hyalumatrix MoomWhite' in July 2024, showcases continuous innovation in the medical aesthetics field.
Strategic Diversification
Expansion into photoelectric equipment through the acquisition of JUVA in 2021 and entry into the soft contact lens market via Hebei Xinshikang acquisition demonstrate a strategic approach to diversification.
Intellectual Property Growth
The company's commitment to innovation is evidenced by over 500 patent applications, with more than 100 granted invention patents and dozens of international invention patents by the end of 2023.
Product Portfolio Expansion
Acquiring Hangzhou Aijinglun in 2020 provided access to the refractive lens PRL, further enriching the company's ophthalmic offerings.
Collaborative Growth
Strategic collaborations, such as the one with CHINARES PHARMA for aesthetic medicine, aim to leverage synergies and expand market reach, aligning with the Growth Strategy of Haohai Biological Technology.
The company has encountered market headwinds, including the impact of volume-based procurement on product sales prices in the first half of 2024, which offset gains from higher-margin products. Additionally, a Q1 2025 financial report indicated a revenue decrease of 4.25% to CNY 618.54 million and a net income drop of 7.41% to CNY 90.31 million year-over-year.
Pricing Pressures
Volume-based procurement policies have led to reduced sales prices for key products like ophthalmic intraocular lenses and orthopedic injections, impacting overall revenue streams.
Financial Performance Dip
The first quarter of 2025 saw a decline in both revenue and net income compared to the previous year, indicating short-term financial challenges.
Reputational Risk
In May 2025, the controlling shareholder faced an investigation for suspected insider trading, presenting a significant challenge to the company's reputation and operational stability.
R&D Investment Strategy
Despite challenges, the company maintained a strong commitment to research and development, allocating RMB 238.9293 million in 2024, representing 8.86% of its operating revenue.
Market Access Hurdles
Navigating regulatory approvals and market access for new products, while also adapting to evolving procurement policies, remains an ongoing challenge.
Competitive Landscape
The dynamic nature of the medical technology market requires continuous adaptation to competitive pressures and technological advancements to maintain market share.
Haohai Biological Technology Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Haohai Biological Technology?
The Haohai Biological Technology company journey began with its establishment as a limited liability company in Shanghai, PRC, on January 24, 2007. The company quickly expanded its footprint by acquiring three hyaluronic acid (HA) manufacturers in 2007, solidifying its presence in key medical fields. This period marked significant early growth and strategic positioning for the Haohai Biological Technology company profile.
| Year | Key Event |
|---|---|
| 2007 | Established as a limited liability company and acquired three HA manufacturers, entering ophthalmology, orthopedics, and general surgery sectors. |
| 2010 | Transformed into a joint stock company on August 2. |
| 2012 | Launched 'Martrifill,' its first-generation dermal filler, marking a key development in its product portfolio. |
| 2015 | Listed on the Main Board of the Hong Kong Stock Exchange on April 30 and merged with six intraocular lens (IOL) companies, creating a complete IOL industry chain. |
| 2019 | Achieved a significant milestone by listing on the SSE STAR Market on October 30, becoming the first Chinese biopharmaceutical company dual-listed in Hong Kong and on the STAR Market. |
| 2020 | Acquired Hangzhou Aijinglun for refractive lenses and introduced its third-generation dermal filler, Hyalumatrix. |
| 2021 | Expanded into photoelectric equipment through the acquisition of JUVA, invested in Eirion (a botulinum toxin company), and secured exclusive distribution rights for two orthokeratology (OK) lens brands. |
| 2024 | Received approval for 'Hyalumatrix MoomWhite,' the world's first organic cross-linked HA Dermal Filler, in July. Reported full-year revenue of CNY 2,697.66 million on December 31. |
| 2025 | Reported Q1 2025 revenue of CNY 618.54 million on March 31. Announced plans in May for simultaneous Phase III trials of its topical botulinum toxin product in China and the USA. Announced a strategic cooperation with CHINARES PHARMA in June for aesthetic medicine. A board meeting is scheduled for August 22 to review interim results. |
Focus on Medical Aesthetics and Ophthalmology Innovation
As of May 2025, a significant portion of the company's R&D efforts are directed towards medical aesthetics and ophthalmology, with nine projects in each area out of a total of 23. This strategic focus underscores the company's commitment to expanding its innovative product lines in these high-growth sectors.
Global Expansion of Topical Botulinum Toxin
The company plans a simultaneous launch of its topical botulinum toxin product in both China and the United States. This dual-market entry strategy highlights its ambition for international reach and its confidence in this innovative product.
Continued Investment in Research and Development
In 2024, the company invested RMB 238.9293 million in R&D, representing 8.86% of its operating revenue. This sustained investment is crucial for driving innovation and maintaining a competitive edge in the rapidly evolving biomedical industry, aligning with its Marketing Strategy of Haohai Biological Technology.
Financial Growth and Shareholder Value Enhancement
Analysts project earnings and revenue growth of 12.9% and 12.5% per annum, respectively. The company also plans to repurchase up to 10% of its H shares in 2025 to optimize its capital structure and enhance shareholder value.
Haohai Biological Technology Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Haohai Biological Technology Company?
- What is Growth Strategy and Future Prospects of Haohai Biological Technology Company?
- How Does Haohai Biological Technology Company Work?
- What is Sales and Marketing Strategy of Haohai Biological Technology Company?
- What are Mission Vision & Core Values of Haohai Biological Technology Company?
- Who Owns Haohai Biological Technology Company?
- What is Customer Demographics and Target Market of Haohai Biological Technology Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.